Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

About

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma.

Primary Purpose

Treatment

Study Type

Interventional

Phase

Phase 2

Gender

All

Healthy Volunteers

No

Minimum Age

18 Years

Maximum Age

N/A

Documented diagnosis of multiple Mmyeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and anti-B cell maturation antigen (BCMA) therapy], and at least 3 prior lines of therapy (LOT).
Documented disease progression during or after their last anti-myeloma regimen as per IMWG.
Participants must have measurable disease during screening.
Have measurable disease during screening.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Active or history of central nervous system involvement with MM.
Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis.
Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.